Celanese's revenue has grown at a 7.3% annualized rate over the past 4 quarters, reaching $14.5 billion in the most recent period. More impressively, the company's net margin has expanded from 5.5% a year ago to 9.0% currently. This margin improvement, combined with 12.4% ROIC, suggests Celanese is effectively allocating capital and driving operational efficiency. Celanese's strategy of focusing on specialty chemical products, which tend to have higher margins than commodity chemicals, has paid off. The company has divested lower-margin businesses while investing in growth areas like engineered materials and acetyl intermediates. This portfolio optimization has strengthened Celanese's competitive positioning and enabled it to achieve industry-leading profitability. Looking ahead, Celanese has a strong balance sheet with a debt-to-equity ratio of 0.4, providing flexibility for further strategic initiatives. The company's robust free cash flow generation, which has grown from $1.2 billion to $2.0 billion over the past year, can support continued investment in high-return projects or shareholder-friendly actions like dividends and buybacks. Given Celanese's attractive combination of consistent revenue growth, expanding margins, and prudent capital allocation, I believe the stock is well-positioned to outperform. While the shares are not cheap at 15x forward earnings, I see the premium valuation as justified by the company's solid fundamentals and compelling long-term prospects.

Research these companies